“Since an approval in the UK would allow patients from all over the world to seek treatment, I suspect there will be more than enough people that have the money to pay for the treatment to keep the folks at Sawston busy while Eden is being certified.”
- BS. Specials is a leading indicator illustrating thats not how it works when therapies are around $200k. JAMA publication has been out for almost 2 years as well. Yet limited to no demand because most people don’t have that kind of money.
“Sometimes BP pays big bucks for Phase 2 drug candidates, in the billions of $. There is no immediate payback there either and a lot higher risk than NWBO at this point. It's called investing for the future. In the case of NWBO I think it will be called not wanting to be left behind. NWBO patents are worth a lot of money once the treatment is approved. I think those patents will make it more difficult for other companies to enter the DC space with any capacity.”
- No argument here. If BP was interested in investing they would have done it by now. TLD announced around 2.5 years ago, JAMA has been out for almost 2 years, MIA approval for over 18 months, and we are sitting on the cusp of UK approval. Why wait to get involved and why not jump ahead of the many competitors wanting to dominate oncology space? We have completed a successful phase 3 after all!
Watch for another carrot (Flaskworks) to be dangled when no BP shows up at UK approval.
News 
Market Data 
Discover 
AI
